Mealey's (January 25, 2017, 2:53 PM EST) -- BOSTON — Plaintiffs in the Zofran birth defect multidistrict litigation on Jan. 19 asked the judge to certify questions to five state supreme courts about whether a brand-name drug maker that creates a market for an off-label use of a drug can be liable under state law for misrepresentation (In Re: Zofran [Ondansetron] Products Liability Litigation, MDL Docket No. 15-md-2657, D. Mass.)....